The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials

Najim, Omar; Seghers, Sofie; Sergoynne, Laurine; Gaver, Hélène Van; Papadimitriou, Konstantinos; Wouters, Kristien; Trinh, Xuan Bich; Huizing, Manon; Tjalma, Wiebren

doi:10.1016/j.bbcan.2019.188315

Cited by 35 publications

(34 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 ) [78] , [79] . The ESR1-related tumours are generally associated with poor prognosis attributed to the aggressive biology of the tumour, progression and recurrence of disease, and metastasis [80] . Mutations in ESR1 serves as an essential biomarker to predict prognosis and alter treatment options to manage ER + breast cancers.…”

Section: Artificial Intelligence and Translational Oncologymentioning

confidence: 99%

Artificial intelligence (AI) and big data in cancer and precision oncology

Dlamini

Francies

Hull

et al. 2020

Computational and Structural Biotechnology Journal

217

View full text Add to dashboard Cite

show abstract

Section: Artificial Intelligence and Translational Oncologymentioning

confidence: 99%

Artificial intelligence (AI) and big data in cancer and precision oncology

Dlamini

Francies

Hull

et al. 2020

Computational and Structural Biotechnology Journal

217

View full text Add to dashboard Cite

show abstract

“…Hormone receptors (HRs), including oestrogen receptor (ER) and/or progesterone receptor, are expressed in approximately 70% of breast cancers [ 1 ]. Endocrine manipulation is the principal treatment for HR-positive breast cancer patients, both in the early and advanced stages of the disease [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Endocrine manipulation is the principal treatment for HR-positive breast cancer patients, both in the early and advanced stages of the disease [ 2 ]. However, intrinsic and acquired resistance to endocrine therapy is an immense challenge in the clinic [ 1 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

Liu

Sun

et al. 2020

The Breast

View full text Add to dashboard Cite

Background We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy. Methods All patients with HR-positive metastatic breast cancer treated with sirolimus plus endocrine therapy between December 2017 and July 2018 at the Cancer Hospital, Chinese Academy of Medical Sciences were consecutively and retrospectively reviewed. Mutations in circulating tumour DNA (ctDNA) were assayed for 1021 tumour-related genes via gene panel target capture-based next-generation sequencing. Results Thirty-six patients with metastatic breast cancer treated with sirolimus plus endocrine therapy were included. The progression-free survival (PFS) rates between the sirolimus group and everolimus group were similar, and the median PFS was 4.9 months and 5.5 months, respectively (hazard ratio 1.56, 95% CI 0.86–2.81, P = 0.142). The objective response rate in the 36 patients was 19.4%, and the clinical benefit rate was 41.7%. Lipid metabolism disorder was the most common adverse event (69.4%), and 13.9% of patients had stomatitis. Most (94.4%) adverse events were grade 1–2. Twenty patients (55.6%) underwent ctDNA analysis before receiving sirolimus therapy. For patients who received less than 3 lines of chemotherapy, those with PI3K/Akt/mTOR pathway alterations had a better response to sirolimus than those without alterations, with a median PFS of 7.0 months vs 4.3 months (hazard ratio = 0.01, 95% CI 0.00–0.34, P = 0.010). Conclusions Sirolimus is a potentially effective treatment option for patients with HR-positive advanced breast cancer.

show abstract

“…Accumulating evidence showed that genes, proteins, and several pathways are involved in the occurrence and progression of BC, and the precise molecular mechanisms are still unclear. To date, surgery is the first choice for early-stage BC patients, but most clinically diagnosed advanced BC patients are forced to accept chemotherapy [ 5 ], radiotherapy [ 6 ], endocrine therapy [ 7 ], or biotherapy [ 8 ]. The management of the disease is primarily to improve quality of life (QOL) and prevent disease from recurring.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Aidi Injection as an Adjuvant Therapy on Advanced Breast Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chai

Chen

Wen

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Aidi injection (ADI) is being used widely for breast cancer in China. However, the efficacy and safety of it need to be summarized. We conducted a systematic review and meta-analysis to compare ADI and non-ADI treatment for advanced breast cancer. Methods. We searched PubMed, EMBASE, CNKI, SinoMed, and CENTRAL from inception to Jan 2020 for randomized controlled trials (RCTs) with diagnosis of advanced breast cancer that compared the efficacy of ADI with non-ADI treatment. Two researchers screened the literature, extracted data, and evaluated risk of bias separately. The primary outcomes were overall response rate (ORR) and disease control rate (DCR). The secondary outcomes included the QOL, immune cells, and adverse events. Review Manager software was used for estimating risks of bias of included studies, data analysis, and plotting. The sensitivity analysis and the publication bias test were performed using the R language. I2 and chi-square tests were used to estimate heterogeneity. If P>0.1 or I2 < 40%, the fixed-effect model meta-analysis was performed. A random or fixed-effect analysis was used depending on the heterogeneity testing. Weighted mean difference (WMD) or standard mean difference (SMD) was used for analysis of continuous data, and the rate ratio (RR) was calculated for the dichotomous variable, respectively. Results. We included 14 studies with 1006 patients diagnosed as advanced breast cancer in total. The pooled effect showed that ADI increased ORR in advanced BC patients as an add-on therapy with little heterogeneity (RR = 1.14, 95% CI 1.03–1.27). DCR in BC patients could not be improved by ADI. ADI improved the KPS score in BC patients compared with chemotherapy alone (MD = 3.26, 95% CI 1.74–4.78). There were no improvements on immune markers except CD4/CD8 and NK%. Serum tumor markers CEA and CA153 were decreased while treated with ADI, but only one trial was involved. ADI decreased the numbers of myelosuppression in advanced BC patients, and AST, ALT, γ-GT, and CK-MB were all decreased. The sensitivity evaluation indicated that the result of the pooled effect size had good stability. Conclusion. This meta-analysis suggested that based on the existing evidence, treatment with ADI significantly changed the ORR of patients with advanced BC and improved their quality of life with few side effects. However, more randomized trials involving larger samples should be considered, and detailed mechanisms are needed to be uncovered.

show abstract

The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials

Cited by 35 publications

References 36 publications

Artificial intelligence (AI) and big data in cancer and precision oncology

Artificial intelligence (AI) and big data in cancer and precision oncology

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

Efficacy and Safety of Aidi Injection as an Adjuvant Therapy on Advanced Breast Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About